Johnson and Johnson saw enormous potential in one key piece of R & D: a "vessel closure device" (VCD) which uses a synthetic bioabsorbable polymer to close the site of an arterial puncture made during surgery. They predict that soon after clinical testing next year, the instruments will be available for use worldwide in around 8 million heart operations every year.
嬌生公司看中他們研發中的關鍵技術──血管止血器材，預計明年進入臨床實驗後，很快可以嘉惠每年全球 800 萬名施行心導管手術的患者。